TAGCyx Biotechnologies

07/05/2026

We are pleased to announce that our research on the development of an apheresis treatment for preeclampsia has been accepted and published in Science Reports. Title: Selective removal of soluble FLT-1 using a high-affinity DNA aptamer for potential apheresis treatment of preeclampsia. Authors: Kensuke Owari, Haishun Piao, Miyuki Hori, Kazunobu Futami
https://www.nature.com/articles/s41598-026-50826-2
We are eager to develop the efficacious treatment for preeclampsia patients.

Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that has been associated with elevated levels of soluble fms-like tyrosine kinase-1 (sFLT-1), which is thought to contribute to impaired angiogenesis by binding and neutralizing angiogenic factors such as Vascular Endothelial Growth Fac...

27/03/2026

Our CEO, Chizuko Koseki had an interview with Tokyo University IPC venture capital.
The article is seen here.

独自の基盤技術で核酸アプタマー（※）を創出し、薬品に活用することで、次世代の新薬モダリティ（治療手段）に取り組んでいるタグシクス・バイオ株式会社。抗体医薬と同様に、標的タンパク質へ特異的に作用するアプ...

04/02/2026

2月20日に弊社代表の古関が、、第17回次世代モダリティセミナー ～核酸アプタマー医薬品の可能性～のイベントにて講演をいたします。
https://www.link-j.org/event/article-50420.html #:~:text=%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9%E3%83%A9%E3%83%B3%E3%82%AD%E3%83%B3%E3%82%B0%20%C2%B7%201.%20MEDISO%E3%82%BB%E3%83%9F%E3%83%8A%E3%83%BC%E3%82%B7%E3%83%AA%E3%83%BC%E3%82%BA%EF%BD%9E%E5%8C%BB%E7%99%82%E7%B3%BB%E3%83%99%E3%83%B3%E3%83%81%E3%83%A3%E3%83%BC%E3%81%AE%E5%A3%81%E3%82%92%E8%B6%85%E3%81%88%E3%82%8B%EF%BD%9E%20vol.20.%E4%BA%8B%E6%A5%AD%E8%A8%88%E7%94%BB%E7%B7%A8%EF%BC%9A%E5%9F%BA%E7%A4%8E%E3%81%8B%E3%82%89%E5%A7%8B%E3%82%81%E3%82%8BTPP%E3%81%A5%E3%81%8F%E3%82%8A%E3%81%AE%E9%81%93%E3%81%97%E3%82%8B%E3%81%B9%20%C2%B7%202.

28/01/2026

We have entered into an alliance with FRONTEO which has an unique proprietary Drug Discovery AI platform. Please see press release here.

タグシクス・バイオは革新的な新規人工塩基対技術を用いた創薬プラットフォーム技術によってDNAアプタマーを創出します。抗体に続く次世代の新薬モダリティであり、私達は効果が高くかつ安全性の高い医薬品を、安価に...

28/10/2025

臨床試験開始のお知らせ
We are very pleased to inform that our partner in the US, CAGE Bio has started a clinical trial with very potent DNA aptamer we have generated. This product, combining two innovative technologies, ionic liquid of CAGE Bio and a very potent IFNɤ ssDNA aptamer of TAGCyx Biotechnologies in Japan could change Vitligo treatment paradigm in the future. 👍
タグシクス・バイオが、導出した強力なインターフェロンɤに拮抗するアプタマーが米国のCAGEBio社により白斑の患者さんを対象とした臨床試験が開始されました。チームの努力が次第に臨床段階の開発ステージに進みつつあります。

/PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced...

10/10/2025

It was fruitful event at BioJapan.

Today is the last day of three inspiring days at BioJapan 2025 here in Yokohama. I’ve attended BioJapan before, but each time I’m reminded how Japan continues to stand out for research and innovation of the highest caliber. That excellence was once again highlighted by two newly announced Nobel ...

19/09/2025

Let us be aware this devastated disease. TAGCyx team is trying to develop the efficacious treatment for this disease.

Interstitial cystitis (in-ter-stish-uhl sĭ-stī’tĭs), or as we call it, IC, is a condition that consists of recurring pelvic pain, pressure, or discomfort in the bladder and pelvic region.

18/09/2025

TAGCYx team is working hard to bring a good treatment for Hunner type interstitial cystitis. Hope this intractable diseases will have an excellent medicine, our TAGX-0003 in the future😃.

September marks Interstitial Cystitis (IC) Awareness Month, a time to shine a spotlight on a chronic condition that affects millions but often goes unnoticed. For the 4-12 million people potentially living with IC, the struggle is real—yet many may feel their pain and discomfort are dismissed due to its invisibility and the complexity of diagnosis. Now is the perfect time to learn about the symptoms, causes, and available treatments for this condition, and to help those who live with IC feel seen and understood.

Continue reading on The Health Column: https://brnw.ch/21wVHII

29/12/2024

Our office will be closed Dec 28th-Jan5th. We wish 2025 will be a great year to everybody. See you in the new year!

06/12/2024

TAGCYx has been selected to attend in
Shonan Health Innovation Conference in Boston（SHIC）. Dr. Gen Watanabe, COO made a pitch talk at the conference on Wednesday, December 4.